Skip to main
NXTC
NXTC logo

Nextcure (NXTC) Stock Forecast & Price Target

Nextcure (NXTC) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 64%
Buy 18%
Hold 9%
Sell 9%
Strong Sell 0%

Bulls say

NextCure Inc. is positioned favorably within the biopharmaceutical sector, with promising preclinical data showcasing superior efficacy for its product candidates LNCB74 and NC181 against current treatment standards, particularly in endometrial cancer and Alzheimer's disease. The company's innovative approaches, such as utilizing a proprietary glucuronidase linker for LNCB74, support its differentiation in a competitive landscape that includes multiple clinical-stage players targeting B7-H4. Furthermore, ongoing patient enrollment in NC181's second cohort indicates a positive safety profile, reinforcing the overall outlook for the company's pipeline advancements and potential market impact.

Bears say

NextCure Inc faces challenges following the discontinuation of Pfizer's B7-H4 ADC program, which raises concerns about the viability of its own B7-H4 targeted therapy, LNCB74, in light of clinical data indicating a lack of meaningful improvement over standard of care. Additionally, the company's operating expenses in the fourth quarter of 2024 exceeded expectations, contributing to a negative financial outlook. The decision to lower the price target reflects broader concerns regarding the effectiveness of NextCure's product candidates and their potential for commercialization amid rising operational costs.

Nextcure (NXTC) has been analyzed by 11 analysts, with a consensus rating of Buy. 64% of analysts recommend a Strong Buy, 18% recommend Buy, 9% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nextcure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nextcure (NXTC) Forecast

Analysts have given Nextcure (NXTC) a Buy based on their latest research and market trends.

According to 11 analysts, Nextcure (NXTC) has a Buy consensus rating as of Sep 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nextcure (NXTC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.